Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2015 Jan 01;873:401-9. doi: 10.1124/mol.114.096693.
Show Gene links
Show Anatomy links
Concatenated hERG1 tetramers reveal stoichiometry of altered channel gating by RPR-260243.
Wu W
,
Gardner A
,
Sanguinetti MC
.
Abstract
Activation of human ether-a-go-go-related gene 1 (hERG1) K(+) channels mediates repolarization of action potentials in cardiomyocytes. RPR-260243 [(3R,4R)-4-[3-(6-methoxy-quinolin-4-yl)-3-oxo-propyl]-1-[3-(2,3,5-trifluorophenyl)-prop-2-ynyl]-piperidine-3-carboxylic acid] (RPR) slows deactivation and attenuates inactivation of hERG1 channels. A detailed understanding of the molecular mechanism of hERG1 agonists such as RPR may facilitate the design of more selective and potent compounds for prevention of arrhythmia associated with abnormally prolonged ventricular repolarization. RPR binds to a hydrophobic pocket located between two adjacent hERG1 subunits, and, hence, a homotetrameric channel has four identical RPR binding sites. To investigate the stoichiometry of altered channel gating induced by RPR, we constructed and characterized tetrameric hERG1 concatemers containing a variable number of wild-type subunits and subunits containing a point mutation (L553A) that rendered the channel insensitive to RPR, ostensibly by preventing ligand binding. The slowing of deactivation by RPR was proportional to the number of wild-type subunits incorporated into a concatenated tetrameric channel, and four wild-type subunits were required to achieve maximal slowing of deactivation. In contrast, a single wild-type subunit within a concatenated tetramer was sufficient to achieve half of the maximal RPR-induced shift in the voltage dependence of hERG1 inactivation, and maximal effect was achieved in channels containing three or four wild-type subunits. Together our findings suggest that the allosteric modulation of channel gating involves distinct mechanisms of coupling between drug binding and altered deactivation and inactivation.
Abbruzzese,
Modification of hERG1 channel gating by Cd2+.
2010, Pubmed,
Xenbase
Abbruzzese,
Modification of hERG1 channel gating by Cd2+.
2010,
Pubmed
,
Xenbase
Andersen,
Stoichiometry for activation of neuronal α7 nicotinic receptors.
2013,
Pubmed
Curran,
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
1995,
Pubmed
Fenichel,
Drug-induced torsades de pointes and implications for drug development.
2004,
Pubmed
Garg,
Molecular determinants for activation of human ether-à-go-go-related gene 1 potassium channels by 3-nitro-n-(4-phenoxyphenyl) benzamide.
2011,
Pubmed
,
Xenbase
Gerlach,
Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574).
2009,
Pubmed
Gianulis,
Direct interaction of eag domains and cyclic nucleotide-binding homology domains regulate deactivation gating in hERG channels.
2013,
Pubmed
Goldin,
Expression of ion channels by injection of mRNA into Xenopus oocytes.
1992,
Pubmed
,
Xenbase
Gustina,
The eag domain regulates hERG channel inactivation gating via a direct interaction.
2013,
Pubmed
,
Xenbase
Hurst,
Potassium channel assembly from concatenated subunits: effects of proline substitutions in S4 segments.
1996,
Pubmed
,
Xenbase
Kang,
Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
2005,
Pubmed
Keating,
Molecular and cellular mechanisms of cardiac arrhythmias.
2001,
Pubmed
McCormack,
Tandem linkage of Shaker K+ channel subunits does not ensure the stoichiometry of expressed channels.
1993,
Pubmed
,
Xenbase
Ogielska,
Cooperative subunit interactions in C-type inactivation of K channels.
1996,
Pubmed
,
Xenbase
Perry,
Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.
2007,
Pubmed
,
Xenbase
Perry,
PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance.
2009,
Pubmed
,
Xenbase
Sack,
How to validate a heteromeric ion channel drug target: assessing proper expression of concatenated subunits.
2008,
Pubmed
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Sanguinetti,
HERG1 channel agonists and cardiac arrhythmia.
2014,
Pubmed
Schreibmayer,
Voltage clamping of Xenopus laevis oocytes utilizing agarose-cushion electrodes.
1994,
Pubmed
,
Xenbase
Stühmer,
Electrophysiological recording from Xenopus oocytes.
1992,
Pubmed
,
Xenbase
Thomson,
Concerted all-or-none subunit interactions mediate slow deactivation of human ether-à-go-go-related gene K+ channels.
2014,
Pubmed
,
Xenbase
Trudeau,
HERG, a human inward rectifier in the voltage-gated potassium channel family.
1995,
Pubmed
Wu,
Stoichiometry of altered hERG1 channel gating by small molecule activators.
2014,
Pubmed
,
Xenbase
Wu,
Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K+ channels.
2014,
Pubmed
,
Xenbase
Zeng,
Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
2006,
Pubmed
Zhou,
Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
2005,
Pubmed
daCosta,
Stoichiometry for drug potentiation of a pentameric ion channel.
2013,
Pubmed
